Nationwide trends in the epidemiology of diabetic foot complications and lower-extremity amputation over an 8-year period

Cheng-Wei Lin,1 David G Armstrong,2 Chia-Hung Lin,1 Pi-Hua Liu,1,3 Shih-Yuan Hung,1,4 Shu-Ru Lee,3 Chung-Huei Huang,1 Yu-Yao Huang1,4,5

ABSTRACT

Objective To study the prevalence and trends of lower extremity complications of diabetes over an 8-year period in a single nation.

Research design and methods Nationwide data for people with type 2 diabetes (T2D) and diabetic foot complications (DFCs) were analyzed over an 8-year period (2007–2014) from National Health Insurance Research Database using the International Classification of Diseases, Ninth Revision disease coding. The DFCs were defined as ulcers, infections, gangrene, and hospitalization for peripheral arterial disease (PAD). Trends of patient characteristics, foot presentation, and the execution of major procedures were studied, including lower-extremity amputations (LEAs).

Results Along with the T2D population increasing over time, the absolute number of people with DFCs increased by 33.4%, but retained a prevalence of around 2% per year. The annual incident of LEAs decreased from 2.85 to 2.06 per 1000 T2D population (p<0.001) with the major LEA proportion decreasing from 56.2% to 47.4% (p<0.001).

The mean age of patients increased from 65.3 to 66.3 years and most of the associated comorbidities of diabetes were increased. For example, end-stage renal disease increased from 4.9% to 7.7% (p<0.001). The incidence of gangrene on presentation decreased from 14.7% to 11.3% (p<0.001) with a concomitant increase in vascular interventions (6.2% to 19.5%, p<0.001).

Conclusions DFCs remain a sustained major medical problem. These nationwide long-term data suggest trends toward older people with greater comorbidities such as PAD and renal disease. Nevertheless, promising trends of reducing gangrene on presentation paired with increases in vascular interventions support continued vigilance and rapid, coordinated interdisciplinary diabetic foot care.

INTRODUCTION

Diabetic foot complications (DFCs) are major sequelae of diabetes and contribute to most causes of non-traumatic lower-extremity amputations (LEAs) worldwide. In addition, patients with DFCs have been known to have higher recurrence rate of ulcers and worse survival than that of many common cancers. The medical expense of patients with these complications is even higher than the most costly cancers; moreover, patients who received LEAs usually had worsened consequences including lower self-esteem, shortened lifespan, and the burden of social care.

The US has previously reported a decreasing trend in LEAs but a disturbing reversal has been noted in recent years in patients with DFCs. Similar trends have been reported in people with end-stage renal diseases. Nevertheless, any explanation of the trend of LEAs is challenging because of scant information available. Information regarding risk factors for LEAs in treating patients with DFCs such as lower-extremity amputation.
as age,\textsuperscript{13} degree of peripheral arterial diseases (PADs)\textsuperscript{14} and infection,\textsuperscript{15} renal function,\textsuperscript{16} and nutritional status\textsuperscript{17} is required for further investigations.

Because of the robust and comprehensive nature of the Taiwan National Health System database, we were able to report the in-hospital foot diseases characteristics between years 2000 and 2009.\textsuperscript{18} The annual incidence of diabetes-related LEA in Taiwan between 1998 and 2007 was 3.79 and 2.27/1000/year, respectively.\textsuperscript{19}

The present study was conducted to better understand the prevalence and time trends of patients with DFCs between 2007 and 2014, including demographics of patients, affected foot and major procedures introduced to treat these patients, and LEAs.

RESEARCH DESIGN AND METHODS
Study population and source
The present study was based on data collected over an 8-year period (2007–2014) derived from the Taiwan National Health Insurance Research Database (NHIRD). The Taiwanese government implemented its National Health Insurance (NHI) system in 1995. This provided coverage for 95% of the population in 2000, which increased to 98% in 2005 and 99.6% of the total 23-million people in Taiwan in 2009.\textsuperscript{18} Large computerized administrative and claims databases derived from this programme have provided diagnoses, procedures, and prescriptions of inpatient and outpatient records. Patients with diabetes mellitus were identified through the International Classification of Diseases, Ninth Revision diagnostic code of 250 (except 250.01, 250.03 for type 1 diabetes) at least once during hospital admission or three or more times for ambulatory clinic patients in each calendar year.

Definition of diabetic foot complications and comorbidities
DFCs include diabetic foot infection, severe PADs, and foot ulcers. The diabetic foot infections were identified by foot cellulitis or abscess (680.6, 680.7, 681.10, 682.6, 682.7); osteomyelitis (730.06, 730.07, 730.16, 730.17, 730.26, 730.27, 730.96, 730.97); and necrotizing fasciitis (728.86, 040.0). Severe PADs were identified by the presentation of gangrene (785.4, 440.24) or hospitalization for PAD (440.2, 440.3, 440.4, 443.81, 443.89, 443.9, 444.22, 445.02, 785.4). Foot ulcers included the diagnostic codes of 707.06, 707.07, 707.1, 892, and 893.

LEAs were identified by diagnostic codes of V49.70, V49.71, V49.72, V49.73, V49.74 and procedure codes of 84.11, 84.12 for minor LEA and by V49.75, V49.76, V49.77 and 84.14, 84.15, 84.17 for major LEA, respectively in each calendar year. Only the highest-level amputation was enrolled for per-patient-per-calendar-year measure to prevent overestimation of the amputation amount because of possible multistep procedures for one person.

The comorbidities of patients with DFCs were identified based on the records of coding for hypertension (401, 402, 403, 404, 405), dyslipidemia (272.0, 272.1, 272.2, 272.3, 272.4), diabetic retinopathy (362, 250.5), diabetic neuropathy (250.6), diabetic nephropathy (250.4, 585, 586, V42.0, V45.1, V56, 403, 404), end-stage renal disease (585.5, 585.6, 586, V45.1, V45.1, V56.X, 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93), coronary heart diseases (410, 411, 412, 414.00–414.07, 414.2–414.9), heart failure (428), and cerebral vascular accident (433, 434, 435, 436, 437.1, 430, 431, 432) before the diagnosis of DFCs.

Vascular interventions and medical expenditure
The endovascular treatments were defined as the procedure codes for percutaneous transluminal angioplasty (PTAs), either simple PTA (33074B) or complicated PTA (33115B). The bypass graft surgery was defined by code of 69004B. These specific procedure codes of NHIRD were provided in the online supplementary file 1. To avoid the noise of coding for arterial-venous shunt treatment, the patients with end-stage renal disease who received procedure of simple PTA were excluded.

The annual medical expenditure of each patient was provided from NHI. All dollar values were adjusted and presented in 2019 US dollars.

Statistical analysis
The demographic characteristics including age, gender, comorbidities, and medical cost among patients with diabetes having foot diseases and/or all patients with diabetes were summarized by year using frequencies (proportions) and means (SD) as appropriate. The prevalence was described as a percentage. Within the population of people coded with DFCs, the prevalence and the proportion of the comorbidities, LEAs, phenotypes of foot diseases including ischemic foot, foot infections and foot ulcers, and vascular interventions were analyzed annually. In addition, 95% CIs of diabetic foot prevalence were obtained. Changes in the prevalence and proportion from 2007 to 2014 were analyzed using a Joinpoint regression model. All statistical analyses were performed using the SAS V.9.4 (SAS Institute, Cary, North Carolina, USA) and the Join-point Trend Analysis Software V.4.5.0.1\textsuperscript{20}

RESULTS
As the T2D population rose from 1115556 to 1556988 from year 2007 to 2014, the number of people with T2D and DFCs increased by 33.4% (table 1). Nevertheless, the prevalence of DFCs in patients with T2D was 2.07% in 2007 and 1.98% in 2014, which showed a slight decrease in trend (p for trend=0.024).

The annual expenditure for any medical performance per person with DFCs was constantly higher than that of the T2D population, in a 3.2-fold to 3.4-fold range.

The absolute number of the T2D population suffering from LEAs was 3181 in year 2007–3213 in 2014, with the annual LEAs rate decreasing from 2.85 to 2.06 (p for trend=0.001) per 1000 T2D persons per year. The trends for both major LEA and minor LEA rates were noted to...
**Table 1** Trends of diabetic foot complications among patients with T2D

| Year | Patients with DFC | T2D population | DFCs prevalence, % (95% CI) | Cost*: DFCs/T2D ratio (%) | LEAs (per 1000 subjects with T2D) | Minor LEA | Major LEA | Major/total LEAs (%) |
|------|------------------|----------------|-----------------------------|-------------------|---------------------------------|-----------|-----------|---------------------|
| 2007 | 23068            | 1115556        | 2.07 (2.04 to 2.09)         | 8.8/2.7            | 2.85                            | 1.25      | 1.60      | 56.2                |
| 2008 | 26039            | 1192004        | 2.18 (2.16 to 2.21)         | 8.8/2.7            | 2.91                            | 1.33      | 1.57      | 54.1                |
| 2009 | 27368            | 1269496        | 2.16 (2.13 to 2.18)         | 9.1/2.7            | 2.72                            | 1.29      | 1.43      | 52.7                |
| 2010 | 28729            | 1339223        | 2.15 (2.12 to 2.17)         | 9.1/2.7            | 2.59                            | 1.24      | 1.35      | 52.3                |
| 2011 | 29770            | 1404474        | 2.12 (2.10 to 2.14)         | 9.2/2.7            | 2.68                            | 1.33      | 1.35      | 50.5                |
| 2012 | 30007            | 1472448        | 2.04 (2.02 to 2.06)         | 9.0/2.7            | 2.29                            | 1.14      | 1.15      | 50.3                |
| 2013 | 30332            | 1535613        | 1.98 (1.95 to 2.00)         | 8.9/2.7            | 2.07                            | 1.09      | 0.98      | 47.3                |
| 2014 | 30783            | 1556988        | 1.98 (1.96 to 2.00)         | 8.5/2.6            | 2.06                            | 1.09      | 0.98      | 47.4                |

*Cost unit=US$1000 per one person-years.
DFC, diabetic foot complication; LEA, lower extremity amputations; T2D, type 2 diabetes.

**DISCUSSION**

The results of this large, national, 8-year study suggest that DFCs remain common. The updated nationwide trends in a high-income country might provide more objective information for future management of this complex disease.

**Table 3** Major presentations of DFCs over time

| Year | Foot infection (%) | Foot ulcer (%) | PAD (%) | Osteomyelitis (%) | Necrotizing fasciitis (%) | Foot gangrene (%) |
|------|--------------------|----------------|---------|------------------|-------------------------|------------------|
| 2007 | 59.0               | 38.4           | 28.8    | 6.8              | 7.0                     | 14.7             |
| 2008 | 63.1               | 33.8           | 26.8    | 7.4              | 8.2                     | 11.3             |
| 2009 | 67.2               | 31.7           | 26.2    | 7.7              | 8.5                     | 10.7             |
| 2010 | 69.0               | 30.0           | 25.8    | 7.6              | 8.7                     | 10.3             |
| 2011 | 69.3               | 30.2           | 25.9    | 7.7              | 8.8                     | 10.4             |
| 2012 | 69.5               | 30.3           | 25.9    | 7.8              | 8.9                     | 10.4             |
| 2013 | 69.7               | 30.4           | 25.9    | 7.9              | 9.0                     | 10.5             |
| 2014 | 69.9               | 30.5           | 26.0    | 8.0              | 9.1                     | 10.6             |

**Figure 1** summarizes the major findings of patients with T2D and DFCs. Figure 1A shows the decrement of LEAs over time, with a more significant reduction in major rather than minor LEA. Figure 1B demonstrates the increase of associated MACES; however, no statistical change in the performance of PTAs while bypass surgeries remained at the same rate. Figure 1C shows the significant reduction of foot gangrene, and the increased trend of osteomyelitis and necrotizing fasciitis. Figure 1D panel reveals a four-fold increase in the prevalence of foot infections and the increased trend of osteomyelitis and necrotizing fasciitis. Nevertheless, the prevalence of foot gangrene decreased significantly, from 4.9 in 2007 to 2.7 in 2014 (p<0.001). The prevalence of end-stage renal disease in patients with DFCs increased from 4.9 in 2007 to 7.7 in 2014 (p<0.001). No significant difference was found in the percentage of male gender (from 54.2% to 57.1%, p=0.019). The prevalence of T2D population decreased (p<0.001 for major LEAs and p=0.019 for minor LEAs). Of note, the ratio of major LEA in LEAs decreased from 56.2% to 47.4% (p<0.001).

The results of this large, national, 8-year study suggest that DFCs remain common. The updated nationwide trends in a high-income country might provide more objective information for future management of this complex disease.

**Table 4** Characteristics of patients with T2D and DFCs

| Year | Mean age (years) | Male gender (%) | Hypertension (%) | Dyslipidemia (%) | Diabetic nephropathy (%) | End-stage renal disease (%) |
|------|-----------------|-----------------|------------------|-----------------|-------------------------|---------------------------|
| 2007 | 65.3±12.8       | 54.2            | 68.8             | 34.5            | 14.2                    | 4.9                       |
| 2008 | 66.3±13.6       | 54.8            | 69.0             | 35.2            | 14.7                    | 5.6                       |
| 2009 | 67.3±14.0       | 55.5            | 69.3             | 35.7            | 15.0                    | 5.8                       |
| 2010 | 68.1±14.5       | 56.2            | 70.0             | 36.1            | 15.4                    | 6.0                       |
| 2011 | 68.8±14.9       | 56.8            | 70.3             | 36.6            | 15.9                    | 6.3                       |
| 2012 | 69.4±15.3       | 57.4            | 70.6             | 37.0            | 16.4                    | 6.6                       |
| 2013 | 69.9±15.7       | 58.0            | 70.9             | 37.3            | 16.8                    | 6.9                       |
| 2014 | 70.5±16.1       | 58.6            | 71.2             | 37.6            | 17.2                    | 7.2                       |

**Figure 1** demonstrates the major presentations of DFCs over time. The rate for foot infection increased from 59.6 in 2007 to 63.1 in 2014, with an increased trend of foot infections (p=0.064). The rate of foot ulceration increased from 28.8% to 28.5% (p=0.019). The rate of osteomyelitis increased from 6.8% to 7.4% (p=0.039) and necrotizing fasciitis from 7.0% to 8.2% (p<0.001) were noted. Nevertheless, the prevalence of foot gangrene decreased significantly, from 4.9 in 2007 to 2.7 in 2014 (p<0.001). The prevalence of end-stage renal disease in patients with DFCs increased from 4.9 in 2007 to 7.7 in 2014 (p<0.001). No significant difference was found in the percentage of male gender (from 54.2% to 57.1%, p=0.019). The prevalence of T2D population decreased (p<0.001 for major LEAs and p=0.019 for minor LEAs). Of note, the ratio of major LEA in LEAs decreased from 56.2% to 47.4% (p<0.001).

The results of this large, national, 8-year study suggest that DFCs remain common. The updated nationwide trends in a high-income country might provide more objective information for future management of this complex disease.
Table 2  Descriptive characteristics of patients with DFCs

| Year | 2007    | 2008    | 2009    | 2010    | 2011    | 2012    | 2013    | 2014    | P for trend |
|------|---------|---------|---------|---------|---------|---------|---------|---------|-------------|
| Age (mean, SD) | 65.33±12.84 | 65.84±13.05 | 65.83±13.19 | 65.92±13.34 | 66.27±13.42 | 66.33±13.47 | 66.06±13.58 | 66.30±13.63 |            |
| Age≥60 years | 15305 (66.4) | 17483 (67.1) | 18352 (67.1) | 19356 (67.4) | 20431 (68.6) | 20762 (69.2) | 20713 (68.3) | 21276 (69.1) | 0.003       |
| Male gender (N, %) | 12511 (54.2) | 14387 (55.3) | 15271 (55.8) | 16055 (55.9) | 16616 (55.8) | 16991 (56.6) | 17320 (57.1) | 17584 (57.1) | <0.001      |
| Comorbidities (N, %) | | | | | | | | | |
| Hypertension | 15873 (68.8) | 18232 (70.0) | 19494 (71.2) | 20409 (71.0) | 21673 (72.8) | 21874 (72.9) | 22076 (72.8) | 22476 (73.0) | 0.001       |
| Dyslipidemia | 7960 (34.5) | 9025 (34.7) | 9781 (35.7) | 10570 (36.8) | 11371 (38.2) | 11593 (38.6) | 12419 (40.9) | 13067 (42.5) | <0.001      |
| Diabetic nephropathy | 3286 (14.2) | 3812 (14.6) | 4118 (15.1) | 4667 (16.2) | 4963 (16.7) | 5187 (17.3) | 5157 (17.0) | 5258 (17.1) | 0.001       |
| End-stage renal disease | 1128 (4.9) | 1435 (5.5) | 1735 (6.3) | 2103 (7.3) | 2376 (8.0) | 2421 (8.1) | 2375 (7.8) | 2382 (7.7) | 0.008       |
| Diabetic retinopathy | 452 (2.0) | 520 (2.0) | 502 (1.8) | 540 (1.9) | 507 (1.7) | 497 (1.7) | 403 (1.3) | 377 (1.2) | 0.001       |
| Diabetic neuropathy | 1005 (4.4) | 991 (3.8) | 1035 (3.8) | 1064 (3.7) | 1045 (3.5) | 1045 (3.5) | 949 (3.1) | 960 (3.1) | <0.001      |
| Coronary heart disease | 1309 (5.7) | 1492 (5.7) | 1510 (5.5) | 1551 (5.4) | 1739 (5.8) | 1669 (5.6) | 1784 (5.9) | 1728 (5.6) | 0.667       |
| Heart failure | 740 (3.2) | 824 (3.2) | 920 (3.4) | 1034 (3.6) | 1065 (3.6) | 1075 (3.6) | 969 (3.2) | 924 (3.0) | 0.763       |
| Ischemic stroke | 397 (1.7) | 493 (1.9) | 457 (1.7) | 490 (1.7) | 495 (1.7) | 462 (1.5) | 450 (1.5) | 417 (1.4) | 0.003       |
| Hemorrhagic stroke | 21 (0.1) | 36 (0.1) | 35 (0.1) | 44 (0.2) | 31 (0.1) | 49 (0.2) | 29 (0.1) | 31 (0.1) | 0.740       |
| MACEs* | 2467 (10.7) | 2845 (10.9) | 2922 (10.7) | 3119 (10.9) | 3330 (11.2) | 3255 (10.9) | 3232 (10.7) | 3100 (10.1) | 0.250       |

*MACEs: including coronary heart disease, heart failure, ischemic stroke and hemorrhagic stroke.
DFC, diabetic foot complication; MACE, major adverse cardiac event; N, number of patients.
The incidence of type 1 diabetes has been reported between 2 and 5 per 100 000 person-years, and the prevalence is much lower than those in Western countries. In this survey, the prevalence of type 1 diabetes was found to be <1% (data not provided). To simplify the epidemiological information, this study excluded patients with type 1 diabetes. The observation of the increase of patients with T2D in this study affirms the soaring rate of diabetic prevalence in Asian countries. Between years 2007 and 2014, increases of 39.6% in patients with T2D and 33.4% in patients with T2D and DFCs were found. The prevalence of DFCs in the T2D population was therefore unchanged at around 2% a year and had declining trend.

It is notable that the rates of LEAs were significantly reduced from 2.85 to 2.06 per 1000 T2D population per year, and our data showed this was mainly attributable to the reduction of major LEA. These trends are similar to the reports of Geiss et al in the USA. Nevertheless, the rates of LEAs reported by Geiss et al was higher (5.38–3.07 per 1000 adults of diabetes) and the trend of LEAs in Taiwan consistently decreased without change in more recent years. It is difficult to analyze the difference of LEAs between individual health systems or entire national health services. The type of diabetes, ethnicities, age distribution, comorbidities and the utility of medical resource may all attribute to the difference. Sheen et al reported a similar decrease of LEAs in patients with diabetes between 1998 and 2007 (3.79 and 2.27/1000/year). Although the authors suggested the impact of pay-for-performance programme in Taiwan, this conclusion may be over-reaching because only 12% coverage rate of that programme for patients with diabetes at that time. Understanding the underlying factors might provide beneficial strategies for future foot care.

Along with the lifespan increase in patients with T2D, we are now facing a trend of more aged patients with higher associated comorbidities. This study demonstrates similar trends in patient with DFCs. Of note, in contrast to the trend of patients associated with MACE remaining stable, the association with chronic kidney disease or end-stage renal disease has increased significantly. We know that chronic kidney diseases and especially end-stage renal disease themselves are the major risk factors for LEAs. This association between kidney disease and amputation has induced mandatory foot care education in this subgroup of the T2D population.

From studies reported, it follows that the risk factors reported for LEAs while treating patients with DFCs are age, PAD especially gangrene, severity of infection, nutritional status, and kidney function. For the study period, the trend of increasing age and associated comorbidities should not be the cause of the decreasing trend of LEAs. Although we found decreased trends of patients associated peripheral neuropathy and retinopathy, the role that neuropathy or microvascular circulation has on LEAs in patients with DFCs still remains controversial.

Regarding the affected foot presentation, the trends showed an increase of foot infections, but a decrease of foot infections.
ulcers. More significantly, we noticed a drop of gangrene presentations. Foot gangrene usually suggests critical ischemia with or without infection, and in many situations, is inevitable for certain degrees of LEA. Although direct evidence was not obtained, the continual decrease of gangrene presentations in DFCs over time was mostly likely due to clinical awareness of early management.

The performance of vascular interventions increased dramatically nationwide, from 6.2% of patients in 2007 to 19.5% in 2014. This may result from an increased awareness of the benefit of interdisciplinary treatments for local ulcer or infection and the underlying PADs. As no specific analysis was performed associating this dramatic increase in peripheral artery intervention and reduction in amputation, drawing conclusions should be made with caution. We plan future efforts to specifically assess this potential association.

Any appropriate rate of vascular intervention could not be determined from this study; nevertheless, the PAD prevalence rate ranging from 26.8% to 28.8%, and among the patients with PAD, a gangrene prevalence of 11.3%–14.7% might indicate that 19.5% of vascular procedures were still within reasonable range. This study also shows that along with the increase of vascular procedures, the utility of annual hospitalization or medical cost for patients with DFCs was not increased. In Taiwan, the performance of PTAs increased at a much greater rate than that of bypass surgery. Similar outcomes have been reported.

In this large population database study, several limitations should be considered. The diagnostic codes usually provide limited information; more detailed information, for example, wound classification or the degree of PAD and the successful rate of vascular interventions were lacking. Furthermore, as mentioned above, no specific relationship between increased peripheral artery intervention and amputation was made using these current data. The statistical estimations of the correlation between the clinical characteristics or DFC phenotypes and the LEAs were weak, and their causal relationship requires further prospective study design to be validated.

In conclusion, the DFCs continue to remain a major medical and public health issue as we face patients in increased numbers, age, and comorbidities. Nevertheless, increasing medical attention including early intervention for ulcers to avoid gangrene, and proper medical treatments (in this study, vascular intervention) could provide a decrease in LEA outcomes.
Epidemiology/Health Services Research

11 Geiss LS, Li Y, Hora I, et al. Resurgence of diabetes-related nontraumatic lower-extremity amputation in the young and middle-aged adult U.S. population. Diabetes Care 2019;42:50–4.
12 Harding JL, Pavkov ME, Gregg EW, et al. Trends of nontraumatic lower-extremity amputation in end-stage renal disease and diabetes: United States, 2000–2015. Diabetes Care 2019;42:1430–5.
13 Boyko EJ, Seeleig AD, Ahroni JH. Limb- and person-level risk factors for lower-limb amputation in the prospective Seattle diabetic foot study. Diabetes Care 2018;41:891–8.
14 American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333–41.
15 Lin C-W, Hsu L-A, Chen C-C, et al. C-Reactive protein as an outcome predictor for percutaneous transluminal angioplasty in diabetic patients with peripheral arterial disease and infected foot ulcer. Diabetes Res Clin Pract 2010;90:167–72.
16 Sun J-H, Tsai J-S, Huang C-H, et al. Risk factors for lower extremity amputation in diabetic foot disease categorized by wagner classification. Diabetes Res Clin Pract 2012;95:358–63.
17 Gau B-R, Chen H-Y, Hung S-Y, et al. The impact of nutritional status on treatment outcomes of patients with limb-threatening diabetic foot ulcers. J Diabetes Complications 2016;30:138–42.
18 Huang Y-Y, Lin K-D, Jiang Y-D, et al. Diabetes-Related kidney, eye, and foot disease in Taiwan: an analysis of the nationwide data for 2000–2009. J Formos Med Assoc 2012;111:637–44.
19 Shee J-Y, Kung P-T, Kuo W-Y, et al. Impact of the pay-for-performance program on lower extremity amputations in patients with diabetes in Taiwan. Medicine 2018;97:e12759.
20 Division of Cancer Control & Population Sciences, National Cancer Institute. Joinpoint trend analysis software [Internet]. Available: https://surveillance.cancer.gov/joinpoint/ Accessed 18 June 2019.
21 Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD clinical practice consensus guidelines 2018: definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 2018;19(6):7–19.
22 Chan JCN, Cho NH, Taiima N, et al. Diabetes in the Western Pacific Region—Past, present and future. Diabetes Res Clin Pract 2014;103:244–55.
23 International Diabetes Federation. IDF diabetes atlas. 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. https://diabetesatlas.org/.
24 Won JC, Lee JH, Kim JH, et al. Diabetes fact sheet in Korea, 2016: an appraisal of current status. Diabetes Metab J 2018;42:415–24.
25 World Health Organization. Country and regional data on diabetes: prevalence of diabetes in the WHO South-East Asia Region [Internet]. 2019. Available: https://www.who.int/diabetes/facts-world_figures/en/index5.html [Accessed 18 June 2019].
26 Lee I-T, Hsu C-C, Sheu WH-H, et al. Pay-For-Performance for shared care of diabetes in Taiwan. J Formos Med Assoc 2019;118:664–6.
30350-X.
27 Kalyani RR, Golden SH, Cefalu WT. Diabetes and aging: unique considerations and goals of care. Diabetes Care 2017;40:440–3.
28 Patel VI, Mukhopadhyay S, Guest JM, et al. Impact of severe chronic kidney disease on outcomes of infrainguinal peripheral arterial intervention. J Vasc Surg 2018;68:598–607.e9.
29 Franz D, Zheng Y, Leeper NJ, et al. Trends in rates of lower extremity amputation among patients with end-stage renal disease who receive dialysis. JAMA Intern Med 2018;178:1025–32.
30 Ugwu E, Adeleye O, Gezawa I, et al. Predictors of lower extremity amputation in patients with diabetic foot ulcers: findings from MEDFUN, a multi-center observational study. J Foot Ankle Res 2019;12:34.
31 Schaper NC, Andros A, Apelqvist J, et al. Diagnosis and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the diabetic foot. Diabetes Metab Res Rev 2012;28(Suppl 1):218–24.
32 Shatnawi NJ, Al-Zoubi NA, Hawamdeh HM, et al. Predictors of major lower limb amputation in type 2 diabetic patients referred for hospital care with diabetic foot syndrome. Diabetes Metab Syndr Obes 2018;11:313–9.
33 Lepantalo MJ, Hobbballah R, Raux M, et al. Lower extremity bypass vs endovascular therapy for young patients with symptomatic peripheral arterial disease. J Vasc Surg 2012;56:545–54.
34 Iida O, Nakamura M, Yamauchi Y, et al. 3-Year outcomes of the olive registry, a prospective multicenter study of patients with critical limb ischemia: a prospective, multi-center, three-year follow-up study on endovascular treatment for infra-inguinal vessel in patients with critical limb ischemia. JACC Cardiovasc Interv 2015;8:1493–502.
35 Wisseman JT, Fernandes-Taylor S, Saha S, et al. Endovascular versus open revascularization for peripheral arterial disease. Ann Surg 2017;265:424–30.

REFERENCES

1 Morbach S, Furchert H, Größlinghoff U, et al. Long-Term prognosis of diabetic foot patients and their limbs: amputation and death over 15 years in a diabetes care course of 1 decade. Diabetes Care 2012;35:2021–7.
2 Wukich DK, Rappeport KM. Assessing health-related quality of life in patients with diabetic foot disease: why is it important and how can we improve? the 2017 Roger E. Pecoraro Award Lecture. Diabetes Care 2018;41:391–7.
3 Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med Overseas Ed 2017;376:2367–75.
4 Armstrong DG, Wrobel J, Robbins JM. Guest editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J 2007;4:286–7.
5 Skrepnek GL, Mills JL, Lavery LA, et al. Health care service and outcomes among an estimated 6.7 million ambulatory care diabetic foot cases in the U.S. Diabetes Care 2017;40:936–42.
6 Barshes NR, Sigireddi M, Wrobel JS, et al. The system of care for the diabetic foot: objectives, outcomes, and opportunities. Diabet Foot Ankle 2013;4:doi:10.3402/dfa.v4i0.21847.
7 Holzer LA, Sevela F, Frabeger B, et al. Body image and self-esteem in lower-limb amputees. PLoS One 2014;9:e92943.
8 Gurney JK, Stanley J, Rumball-Smith J, et al. Postoperative death after lower-limb amputation in a national prevalent cohort of patients with diabetes. Diabetes Care 2018;41:1204–11.
9 Lin C-W, Hsu BR-S, Tsai J-S, et al. Effect of limb preservation status and body mass index on the survival of patients with limb-threatening diabetic foot ulcers. J Diabetes Complications 2017;31:180–5.
10 Bommer C, Hesseman E, Sagalova V, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. The Lancet Diabetes & Endocrinology 2017;5:423–30.